Capricor Therapeutics, Inc. Common Stock (CAPR) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with CAPR
Recent news

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
CAPR

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
CAPR

CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
CAPR

Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
CAPR
Technical indicators
- RSI 14
- 43.38
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.05
- SMA 50
- $7.57
- Price above SMA 50
- EMA 50
- $10.25
- Price below EMA 50
- SMA 200
- $22.43
- Price below SMA 200
- EMA 200
- $17.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
CAPR

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
CAPR

CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
CAPR

Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
CAPR

Why Did CAPR Stock Jump 20% After-Hours Today?
Why Did CAPR Stock Jump 20% After-Hours Today?
CAPR

CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
CAPR

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR

CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
CAPR

CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
CAPR

3 Small-Cap Biotechs With Binary Catalysts on the Calendar
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
CAPR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Capricor Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board | 1956 |
| Dr. Linda Marbán Ph.D. | Co-Founder, President, CEO & Director | 1963 |
| Mr. Anthony J. Bergmann M.B.A. | CFO & Corporate Treasurer | 1986 |
| Ms. Karen G. Krasney Esq., J.D. | Executive VP, General Counsel & Secretary | 1953 |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Operating & Science Officer | — |
| Mr. Minghao Sun Ph.D. | Senior Vice President of Quality Control, Research & Product Development | — |
| Mr. Mark Awadalla | Chief Development Officer | — |
| Dr. Micheal Binks M.D. | Chief Medical Officer | — |
| Mr. Michael Maurer | Chief Commercial Officer | — |
| Nathaniel Hogan Ph.D. | Director of Biostatistics of Capricor Therapeutics | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 43.38
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.23
- MACD histogram
- -0.05
- SMA 50
- $7.57
- Price above SMA 50
- EMA 50
- $10.25
- Price below EMA 50
- SMA 200
- $22.43
- Price below SMA 200
- EMA 200
- $17.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $21.00
- Average
- $24.67
- High
- $28.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.6 | -11.3 | -8.7 | |||||||||
| 2022 | +12.3 | +10.4 | -20.4 | -11.7 | +4.3 | -1.7 | +25.3 | +32.6 | +1.4 | -8.9 | -17.8 | -10.9 |
| 2023 | +9.6 | +7.6 | -16.1 | -7.6 | +15.9 | +5.1 | -6.4 | +41.2 | -48.3 | -5.1 | +6.1 | +65.2 |
| 2024 | -21.1 | +3.2 | +48.6 | -25.8 | +6.6 | -15.4 | -16.1 | +16.9 | +248.1 | +33.9 | -2.3 | -29.7 |
| 2025 | +0.5 | +1.3 | -30.6 | +34.0 | -22.4 | -2.7 | -15.7 | -20.5 | +13.9 | -16.8 | -11.9 | +334.0 |
| 2026 | -22.7 | +21.0 | +13.2 | +11.5 | -3.1 | -15.6 | -83.3 | +136.0 | -5.4 | -10.4 |



